Clinical Trial Update: Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing FOLFIRINOX plus panitumumab versus mFOLFOX6 plus panitumumab in RAS/B-RAF wild-type metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRINOX regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan)
• Panitumumab (panitumumab)
• mFOLFOX6 regimen

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING